Trials / Completed
CompletedNCT05216588
Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 149 (actual)
- Sponsor
- ANRS, Emerging Infectious Diseases · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective cohort of patients, receiving pre exposure prophylaxis by Anti-SARS-CoV-2 Monoclonal Antibodies, is designed to evaluate the treatment protection against SARS-CoV-2 variants of concerns
Conditions
Timeline
- Start date
- 2022-01-26
- Primary completion
- 2023-11-03
- Completion
- 2024-10-31
- First posted
- 2022-01-31
- Last updated
- 2025-01-29
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05216588. Inclusion in this directory is not an endorsement.